



Abbott Laboratories (Pakistan) Limited

City Office:

11th & 12th Floors, Ocean Tower, G-3,

Block-9, Main Clifton Road,

Karachi, Sindh 75600

P.O. Box No. 13841, Karachi

Tel: +92-21-38709369, +92-21-32799018

Abbott Laboratories (Pakistan) Limited

Registered Office:

Opp. Radio Pakistan Transmission Centre,

Hyderabad Road, Landhi, Karachi-75120

P.O. Box 7229 Karachi 74400

Tel: +92-21-111-Abbott (111-222-688)

October 27th, 2026

The General Manager
Pakistan Stock Exchange Limited
Stock Exchange Building
Stock Exchange Road
Karachi

Sub: Financial Results for the Nine months and Quarter ended September 30th, 2026

Dear Sir,

We have to inform you that the Board of Directors' of our company in their meeting held on Tuesday, October 27th, 2026 at 11:30 a.m. at the City Office, Abbott Laboratories (Pakistan) Limited, Karachi, considered and approved the financial results of the Company as follows:

	<u>Nine Months Ended</u>		<u>Three Months Ended</u>	
	September 30, 2026	September 30, 2025	September 30, 2026	September 30, 2025
	----- (Rupees in ' 000) -----			
SALES- NET				
Local	57,135,984	53,909,372	19,985,118	18,995,527
Export	1,520,309	2,317,551	644,624	823,607
	<u>58,656,293</u>	<u>56,226,923</u>	<u>20,629,742</u>	<u>19,819,134</u>
Cost of sales	(36,442,164)	(36,886,086)	(12,865,719)	(13,093,197)
GROSS PROFIT	<u>22,214,129</u>	<u>19,340,837</u>	<u>7,764,023</u>	<u>6,725,937</u>
Selling and distribution expenses	(9,042,285)	(8,501,410)	(2,859,975)	(2,974,143)
Administrative expenses	(1,099,517)	(972,482)	(384,932)	(334,287)
Other charges	(1,364,068)	(1,256,699)	(476,660)	(430,365)
Other income	745,997	603,335	176,614	186,590
	<u>(10,759,873)</u>	<u>(10,127,256)</u>	<u>(3,544,953)</u>	<u>(3,552,205)</u>
	11,454,256	9,213,581	4,219,070	3,173,732
Finance costs	(51,788)	(55,363)	(16,145)	(17,659)
PROFIT BEFORE TAXATION	<u>11,402,468</u>	<u>9,158,218</u>	<u>4,202,925</u>	<u>3,156,073</u>
Minimum tax differential	-	(146,989)	159,446	(146,989)
	<u>11,402,468</u>	<u>9,011,229</u>	<u>4,362,371</u>	<u>3,009,084</u>
INCOME TAX				
Current -For the year	(4,455,086)	(3,828,736)	(1,379,231)	(1,181,163)
-Prior year	27,553	-	27,553	-
Deferred	(290,753)	183,225	(466,742)	(5,375)
	<u>(4,718,286)</u>	<u>(3,645,511)</u>	<u>(1,818,420)</u>	<u>(1,186,538)</u>
NET PROFIT FOR THE PERIOD	<u>6,684,182</u>	<u>5,365,718</u>	<u>2,543,951</u>	<u>1,822,546</u>
BASIC AND DILUTED EARNINGS PER SHARE (Rs. per share)	<u>68.28</u>	<u>54.81</u>	<u>25.99</u>	<u>18.62</u>



The Quarterly Report of the Company for the period ended September 30, 2026 will be transmitted through PUCARS separately, within the specified time.

Yours faithfully,
ABBOTT LABORATORIES (PAKISTAN) LIMITED


SYED ANIS AHMED
CHIEF EXECUTIVE &
MANAGING DIRECTOR


CC: To FAMCO Share Registration Services (Pvt) Ltd. 8-F, Next to Hotel Faran, Nursery, Block 6, PECHS, Shahrah-e-Faisal Karachi	CC: To Additional Joint Registrar of Companies Securities Exchange and Commission of Pakistan Company Registration Office Dawood Center, MT Khan Road, Civil Lines Karachi
---	--


ABBOTT LABORATORIES (PAKISTAN) LIMITED
CONDENSED INTERIM STATEMENT OF FINANCIAL POSITION
AS AT SEPTEMBER 30, 2026

	Note	September 30, 2026 ----- Rupees in '000 ----- (Un-audited)	2025 ----- (Audited)
<u>ASSETS</u>			
NON-CURRENT ASSETS			
Property, plant and equipment	6	16,242,572	15,635,851
Intangible assets		672	831
Long-term loans and advances		158,487	141,175
Long-term deposits		32,713	32,628
Long-term prepayments		15,618	12,395
		16,450,062	15,822,880
CURRENT ASSETS			
Stores and spares		670,358	669,690
Stock-in-trade	7	15,832,400	12,447,838
Trade debts		2,948,974	2,820,530
Loans and advances	8	1,143,123	399,086
Trade deposits and short-term prepayments	9	459,926	313,552
Other receivables	10	1,467,912	1,005,069
Taxation - net		806,912	-
Cash and cash equivalents	11	10,374,526	13,337,551
		33,704,131	30,993,316
TOTAL ASSETS		50,154,193	46,816,196
<u>EQUITY AND LIABILITIES</u>			
SHARE CAPITAL AND RESERVES			
Authorised capital			
200,000,000 ordinary shares of Rs.10 each		2,000,000	2,000,000
Issued, subscribed and paid-up capital	12	979,003	979,003
Reserves			
- Capital		2,445,954	2,073,901
- Revenue		31,340,723	28,572,553
		33,786,677	30,646,454
		34,765,680	31,625,457
NON-CURRENT LIABILITIES			
Deferred taxation - net		1,280,717	989,965
Staff retirement benefits		435,011	494,943
Lease liabilities		309,899	329,677
		2,025,627	1,814,585
CURRENT LIABILITIES			
Trade and other payables	13	12,387,316	12,198,722
Unclaimed dividends		123,122	71,155
Unpaid dividends		-	-
Taxation - net		-	246,958
Current maturity of lease liabilities		90,899	158,301
Provisions		761,549	701,018
		13,362,886	13,376,154
CONTINGENCIES AND COMMITMENTS	14		
TOTAL EQUITY AND LIABILITIES		50,154,193	46,816,196

The annexed notes 1 to 20 form an integral part of these condensed interim financial statements.


CHIEF EXECUTIVE OFFICER



DIRECTOR


CHIEF FINANCIAL OFFICER


ABBOTT LABORATORIES (PAKISTAN) LIMITED
CONDENSED INTERIM STATEMENT OF CASH FLOWS
FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2026
(UN-AUDITED)

		September 30, 2026 (Un-audited) ---- Rupees in '000 ----	September 30, 2024 (Un-audited) ---- Rupees in '000 ----
	Note		
CASH FLOWS FROM OPERATING ACTIVITIES			
Cash generated from operations	17	8,193,013	9,020,548
Income taxes paid		(5,481,404)	(3,748,060)
Long-term loans and advances - net		(17,312)	(15,011)
Long-term deposits - net		(85)	(25,200)
Long-term prepayments - net		(3,223)	3,632
Contributions to staff retirement benefit funds		(287,674)	(253,147)
Net movement in provisions		60,531	61,942
Net cash inflow from operating activities		2,463,846	5,044,704
CASH FLOWS FROM INVESTING ACTIVITIES			
Additions to operating fixed assets and CWIP	6.1	(2,117,451)	(1,893,111)
Sale proceeds from disposal of property, plant and equipment		70,758	177,968
Interest income		622,835	345,737
Net cash outflow from investing activities		(1,423,858)	(1,369,406)
CASH FLOWS FROM FINANCING ACTIVITIES			
Finance costs paid		(6,334)	(7,571)
Lease rentals paid		(132,634)	(79,131)
Dividends paid		(3,864,045)	(761,399)
Net cash outflow from financing activities		(4,003,013)	(848,101)
NET INCREASE / (DECREASE) IN CASH AND CASH EQUIVALENTS		(2,963,025)	2,827,197
CASH AND CASH EQUIVALENTS AT BEGINNING OF THE PERIOD		13,337,551	6,182,349
CASH AND CASH EQUIVALENTS AT END OF THE PERIOD	17.2	10,374,526	9,009,546


The annexed notes 1 to 20 form an integral part of these condensed interim financial statements.



CHIEF EXECUTIVE OFFICER



DIRECTOR



CHIEF FINANCIAL OFFICER

ABBOTT LABORATORIES (PAKISTAN) LIMITED
CONDENSED INTERIM STATEMENT OF CHANGES IN EQUITY
FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2026

Share Capital	Reserves					Total Equity
	Capital Reserves		Revenue Reserves		Total	
	Reserve Arising on Merger	Other	General Reserve	Un-appropriated Profit		
----- Rupees in '000 -----						

Balance as at January 01, 2025 (Audited)	979,003	46,097	1,704,384	5,338,422	15,656,730	22,745,633	23,724,636
Final dividend for the year ended December 31, 2024 @ Rs. 10/- per share	-	-	-	-	(979,003)	(979,003)	(979,003)
Employee benefit cost under IFRS 2- 'Share based payments'	-	-	243,476	-	-	243,476	243,476
Total comprehensive income for the period ended September 30, 2025							

Net profit for the period	-	-	-	-	5,365,718	5,365,718	5,365,718
Other comprehensive income for the period	-	-	-	-	-	-	-
	-	-	-	-	5,365,718	5,365,718	5,365,718

Balance as at September 30, 2025 (Un-audited)	979,003	46,097	1,947,860	5,338,422	20,043,445	27,375,824	28,354,827
--	---------	--------	-----------	-----------	------------	------------	------------

Balance as at January 01, 2025 (Audited)	979,003	46,097	2,027,804	5,338,422	23,234,131	30,646,454	31,625,457
Final dividend for the year ended December 31, 2024 @ Rs. 10/- per share	-	-	-	-	(3,916,012)	(3,916,012)	(3,916,012)
Employee benefit cost under IFRS 2- 'Share based payments'	-	-	372,053	-	-	372,053	372,053

Total comprehensive income for the period ended September 30, 2026


Net profit for the period	-	-	-	-	6,684,182	6,684,182	6,684,182
Other comprehensive income for the period	-	-	-	-	-	-	-
	-	-	-	-	6,684,182	6,684,182	6,684,182

Balance as at Septmeber 30, 2026 (Un-audited)	979,003	46,097	2,399,857	5,338,422	26,002,301	33,786,677	34,765,680
--	---------	--------	-----------	-----------	------------	------------	------------


The annexed notes 1 to 20 form an integral part of these condensed interim financial statements.



CHIEF EXECUTIVE OFFICER



DIRECTOR



CHIEF FINANCIAL OFFICER